3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
81
Colorectal Neoplasms
39
Stomach Neoplasms
17
Carcinoma, Non-Small-Cell Lung
15
Liver Neoplasms
14
Neoplasms
11
Melanoma
11
Carcinoma, Renal Cell
11
Esophageal Neoplasms
10
Pancreatic Neoplasms
9
Carcinoma, Transitional Cell
8
Breast Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Small Cell Lung Carcinoma
7
Ovarian Neoplasms
7
Head and Neck Neoplasms
7
Cholangiocarcinoma
7
Rectal Neoplasms
6
Neoplasm Metastasis
6
Colonic Neoplasms
6
Urinary Bladder Neoplasms
5
Gastrointestinal Neoplasms
5
Carcinoma, Merkel Cell
5
Biliary Tract Neoplasms
5
Prostatic Neoplasms
4
Sarcoma
3
Lung Neoplasms
3
Gallbladder Neoplasms
3
Interventions
Irinotecan
10
Fluorouracil
10
Leucovorin
9
Bevacizumab
9
Gemcitabine
8
Paclitaxel
7
Cisplatin
7
Capecitabine
7
Oxaliplatin
6
130-nm albumin-bound paclitaxel
6
Albumin-Bound Paclitaxel
5
napabucasin
4
Sorafenib
4
Drug Therapy
4
Cetuximab
4
pembrolizumab
3
apatinib
3
Radiotherapy
3
Ocoxin
3
Imatinib Mesylate
3
Folfox protocol
3
Everolimus
3
tislelizumab
2
spartalizumab
2
palbociclib
2
entinostat
2
encorafenib
2
camrelizumab
2
anlotinib
2
Sunitinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Digestive System Neoplasms
×
atezolizumab
×
Gastrointestinal
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled